Drugs / PF-06462700
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04350606 | Jul 2020 → Jan 2021 | aplastic anemia | Pfizer | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06462700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04350606 ↗ |
| Action | Inhibit | “PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent.” NCT04350606 ↗ |
| Modality | Protein / enzyme biologic | “It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus...” NCT04350606 ↗ |
| Route | Intravenous | “PF-06462700 administered intravenously at 40 mg/kg/day for 4 days” NCT04350606 ↗ |